|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LINC01619 |
Gene summary for LINC01619 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LINC01619 | Gene ID | 256021 |
| Gene name | long intergenic non-protein coding RNA 1619 | |
| Gene Alias | C12orf79 | |
| Cytomap | 12q21.33 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 256021 | LINC01619 | CCI_1 | Human | Cervix | CC | 9.52e-06 | 6.26e-01 | 0.528 |
| 256021 | LINC01619 | CCI_2 | Human | Cervix | CC | 8.67e-08 | 5.32e-01 | 0.5249 |
| 256021 | LINC01619 | CCI_3 | Human | Cervix | CC | 2.36e-07 | 6.52e-01 | 0.516 |
| 256021 | LINC01619 | AEH-subject1 | Human | Endometrium | AEH | 3.46e-25 | 5.04e-01 | -0.3059 |
| 256021 | LINC01619 | AEH-subject2 | Human | Endometrium | AEH | 4.09e-11 | 3.22e-01 | -0.2525 |
| 256021 | LINC01619 | AEH-subject3 | Human | Endometrium | AEH | 3.02e-19 | 4.64e-01 | -0.2576 |
| 256021 | LINC01619 | AEH-subject4 | Human | Endometrium | AEH | 3.74e-15 | 4.20e-01 | -0.2657 |
| 256021 | LINC01619 | AEH-subject5 | Human | Endometrium | AEH | 4.77e-29 | 6.75e-01 | -0.2953 |
| 256021 | LINC01619 | EEC-subject1 | Human | Endometrium | EEC | 1.12e-23 | 5.27e-01 | -0.2682 |
| 256021 | LINC01619 | EEC-subject2 | Human | Endometrium | EEC | 7.85e-04 | 1.86e-01 | -0.2607 |
| 256021 | LINC01619 | EEC-subject3 | Human | Endometrium | EEC | 1.85e-09 | 3.50e-01 | -0.2525 |
| 256021 | LINC01619 | EEC-subject4 | Human | Endometrium | EEC | 1.91e-17 | 4.61e-01 | -0.2571 |
| 256021 | LINC01619 | EEC-subject5 | Human | Endometrium | EEC | 1.30e-14 | 3.56e-01 | -0.249 |
| 256021 | LINC01619 | TD9 | Human | Lung | IAC | 6.48e-11 | 1.47e+00 | 0.088 |
| 256021 | LINC01619 | RNA-P17T-P17T-2 | Human | Lung | IAC | 3.44e-05 | 6.09e-01 | 0.3371 |
| 256021 | LINC01619 | RNA-P17T-P17T-4 | Human | Lung | IAC | 2.60e-02 | 5.14e-01 | 0.343 |
| 256021 | LINC01619 | RNA-P17T-P17T-6 | Human | Lung | IAC | 9.12e-04 | 6.36e-01 | 0.3385 |
| 256021 | LINC01619 | RNA-P17T-P17T-8 | Human | Lung | IAC | 2.90e-03 | 5.36e-01 | 0.3329 |
| 256021 | LINC01619 | HTA12-15-2 | Human | Pancreas | PDAC | 4.09e-08 | 6.14e-01 | 0.2315 |
| 256021 | LINC01619 | HTA12-16-5 | Human | Pancreas | PDAC | 3.21e-07 | 6.03e-01 | 0.047 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |